DeCART Therapeutics

Enhancing CAR T cells with small molecule targeted protein modulation is the scientific foundation of DeCART. Our goal is to modify the underlying CAR T cell biology ex vivo using small molecules to control levels of certain proteins in the T cells. This ex vivo control of protein levels enhances the phenotype of the T cells, referred to as drug-enhanced CAR T cells, which we believe improves CAR T cell therapies and cancer patient outcomes. DeCART Therapeutics is a biotechnology company founded by a team of scientific and business leaders including Carl H. June, M.D., Joseph A. Fraietta, Ph.D., and Xianxin Hua, M.D., Ph.D. from the University of Pennsylvania; Dana M. Hammill, M.S., M.B.A., formally from the University of Pennsylvania and now Chief Operating Officer of DeCART; and, Arthur T. Sands, M.D., Ph.D. and Pierre Beaurang, Ph.D. from Nurix Therapeutics.